Carole Guillonneau

Co-Founder & Head Of Research, Research Director CNRS, Head Team 2 CR2TI AbolerIS Pharma, Nantes University

Seminars

Wednesday 24th March 2027
Advancing Treg Therapies Through Clinical Validation of Cell-Based & Treg-Modulating Approaches
11:00 am
  • Reviewing early clinical learnings from the first clinical trial of CD8 regulatory T-cellsin transplantation to assess their potential for restoring durable immune tolerance and guiding future cell therapy development
  • Highlighting how translational research into CD8 regulatory T-cells enabled the development of an antibody approach designed to modulate the regulatory T-cell and effector T-cell balance across autoimmune diseases
  • Evaluating emerging clinical experience in rheumatoid arthritis to understand how Treg-modulating strategies can support differentiation, indication expansion, and future clinical development pathways
Carole